Clinical Trial Detail

NCT ID NCT01822756
Title An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Incyte Corporation
Indications

pancreatic cancer

Advanced Solid Tumor

Therapies

Ruxolitinib

Age Groups: adult

No variant requirements are available.